Evidence map›Paper›PMID 30865178›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2019

Brief Report: Kidney Dysfunction Does Not Contribute Significantly to Antiretroviral Therapy Modification in Treatment-Naive PLWH Receiving Initial ART.

Ellen F Eaton, Ashutosh Tamhane, Thibaut Davy-Mendez, Richard D Moore, W Christopher Mathews, Michael S Saag, Michael J Mugavero, Christina M Wyatt, Orlando M Gutierrez

Abstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ellen F EatonDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Ashutosh TamhaneDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Thibaut Davy-MendezRollins School of Public Health, Department of Epidemiology, University of North Carolina, Chapel Hill, NC.
Richard D MooreDepartment of Medicine, Johns Hopkins University, Baltimore, MD.
W Christopher MathewsDepartment of Medicine, University of California, San Diego, CA.
Michael S SaagDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Michael J MugaveroDivision of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Christina M WyattDivision of Nephrology, Department of Medicine, Duke University, Durham, NC.
Orlando M GutierrezDivision of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL.

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
UAB K12 in Patient Centered Outcomes ResearchK12HS023009 · AHRQ · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, KENNETH G · 2014 to 2018
$4.0M
AHRQ HHS K12 HS023009NIAID NIH HHS L30 AI120000NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI094189NIAID NIH HHS U01 AI069918NIDA NIH HHS U01 DA036935
6 · The paper itself

Abstract

backgroundAntiretroviral therapy (ART) durability, time to modification or cessation, has declined. The study objective was to determine whether kidney dysfunction is contributing to reduced durability.

methodsThis retrospective follow-up study of CNICS evaluated treatment-naive PLWH initiating ART between 2007 and 2014. Regimen modification was defined as cessation/modification of any part of the 3-drug ART regimen. We evaluated the role of kidney dysfunction in initial regimen modification as both a mediator and effect measure modifier. Associations of the variables with the ART modification were examined using univariable and multivariable Cox proportional hazard models.

resultsOf 4515 PLWH included in the analysis, 1967 modified their ART. Of those receiving TDF-based ART (n = 3888), 1580 (41%) modified their regimen compared with 387 (62%) receiving other regimens. Overall, the median eGFR decreased by 5 mL/min/1.73 m (quartiles: first = -16, third = 0) from baseline to follow-up. Of the 128 patients with low baseline eGFR (<60 mL/min/1.73 m), the final eGFR remained low in 73% while it increased to above 60 mL/min/1.73 m in 27%. Of the 4387 with normal baseline eGFR, only 135 (3%) had a final eGFR <60 mL/min/1.73 m. Those with low eGFR at the baseline and/or final visits were more likely to modify ART than others (hazards ratio = 1.75, 95% confidence interval: 1.39 to 2.19, P < 0.001). Relative to other regimens, TDF-based ART was less likely to be modified when accounting for numerous clinical and demographic traits.

conclusionsFor patients in our study initiated on ART, including TDF-based ART, in the last decade, kidney dysfunction is not a major factor leading to regimen modification.

Indexed as

AdultAnti-HIV AgentsDrug SubstitutionFemaleGlomerular Filtration RateHIV InfectionsHumansKidney DiseasesMaleMiddle AgedProportional Hazards ModelsRetrospective StudiesAnti-HIV Agents

Identifiers

PMID30865178
PMCPMC6456383

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.